Currently Viewing:
Newsroom
Currently Reading
Opdivo Approved for Adjuvant Treatment of Melanoma in European Union
August 02, 2018 – Samantha DiGrande
This Week in Managed Care: July 27, 2018
July 27, 2018
Cytokine "Backpacks" for T Cells Increase Immune Response in Solid Tumors
July 26, 2018 – Samantha DiGrande
Oncology, CVD, Infectious Disease Most Common Areas for Outcomes-Based Contracts, Avalere Finds
July 26, 2018 – Laura Joszt
Pembrolizumab Meets Primary End Point in Phase 3 Head and Neck Cancer Trial
July 25, 2018 – Samantha DiGrande
Second Biosimilar Approved to Treat Neutropenia
July 24, 2018 – Laura Joszt
Geography Influences Type of Posttreatment Imaging Received After Early Breast Cancer
July 24, 2018 – Allison Inserro
First Targeted Therapy Approved for R/R AML With IDH1 Mutation
July 22, 2018 – Laura Joszt
Global Review Confirms Diabetes Elevates Cancer Risk, Especially in Women
July 22, 2018 – Mary Caffrey

Opdivo Approved for Adjuvant Treatment of Melanoma in European Union

Samantha DiGrande
Bristol-Myers Squibb recently announced that the European Commission has approved nivolumab (Opdivo) for the adjuvant treatment of adult patients with melanoma that have lymph node involvement or metastatic disease and who have undergone complete resection. 
Bristol-Myers Squibb (BMS) recently announced that the European Commission (EC) has approved nivolumab (Opdivo) for the adjuvant treatment of adult patients with melanoma that have lymph node involvement or metastatic disease and who have undergone complete resection. 

With the approval, nivolumab has become the first programmed cell death protein-1 (PD-1) inhibitor to receive an EC approval in the adjuvant setting. The indication also applies for both BRAF mutant and wild-type expressing melanoma patients and makes it the 8th indication for nivolumab across 6 distinct tumor types in the European Union. 

“We are excited that Opdivo has become the first PD-1 agent to receive an approved indication in the adjuvant setting. Today’s approval helps strengthen patients’ confidence in reducing the risk of recurrence and progression of melanoma after primary treatment and furthers our commitment to continuously explore new approaches that benefit more patients,” said Fouad Namouni, MD, head of oncology development at BMS, in a statement.

The approval is based on results from the ongoing phase 3 randomized, double-blind CheckMate-238 trial which is investigating nivolumab versus ipilimumab (Yervoy) in patients who have undergone complete resection of stage IIIB/C or stage IV melanoma. The trial randomized 906 patients 1:1 to receive either nivolumab 3 mg/kg every 2 weeks (n = 453) or ipilimumab 10 mg/kg (n = 453) every 3 weeks for 4 doses, and then every 12 weeks beginning at week 24. Patients were treated until disease recurrence, unacceptable toxicity, or withdrawal of consent for up to 1 year.

The primary endpoint of the trial is recurrence-free survival (RFS), defined as the time between randomization and the date of first recurrence, new primary melanoma, or death. The 18-month RFS was 66.4% for nivolumab (95% confidence interval [CI], 61.8 to 70.6) versus 52.7% for ipilimumab (95% CI, 47.8 to 57.4). 

In addition, adjuvant treatment of nivolumab was well tolerated, with only 14.4% of patients experiencing treatment-related grade 3 or 4 adverse events and 9.7% discontinuing due to toxicity. 

“This is an important new treatment option, as the data support the benefit of nivolumab across a broad range of patients to address concerns around recurrence post-surgery,” said James Larkin, MD, PhD, consultant medical oncologist at The Royal Marsden in a statement.

Related Articles

Contemporary Diagnosis and Management of Advanced Melanoma
Pembrolizumab Combination Fails to Meet Primary Endpoint in Melanoma Study
Opdivo, Yervoy Combination Approved for Certain Colorectal Cancers
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up